COMP <GO>
XRAY vs UFPT // GROSS PROFIT MARGIN
DENTSPLY SIRONA Inc. (NASDAQ) VS. UFP Technologies Inc. (NASDAQ) • 15-METRIC TALLY: XRAY 4
— UFPT 7
▲ GROSS PROFIT MARGIN LEADER: XRAY
LAST: $9.61 (+1.80%) • MKT CAP: $1.92B
gross-margins
50.00%
LAST: $293.30 (+2.55%) • MKT CAP: $2.27B
gross-margins
28.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XRAY VS. UFPT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XRAY | UFPT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 50.00% | 28.30% | +21.70 | XRAY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.00% | 13.90% | -24.90 | UFPT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 25.7x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 12.27% | 4.05% | +8.22 | XRAY | /fcf-yield <GO> |
| Operating Margin | -11.50% | 15.30% | -26.80 | UFPT | /operating-margins <GO> |
| Net Profit Margin | -16.20% | 11.30% | -27.50 | UFPT | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | 19.50% | -22.50 | UFPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 6.68% | 0.00% | +6.68 | XRAY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 8.31 | -7.86 | UFPT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | UFPT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.1 | 44.0 | +11.03 | XRAY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 28.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.92B | $2.27B | -$356.0M | UFPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XRAY REV | UFPT REV | XRAY GROSS % | UFPT GROSS % | XRAY FCF | UFPT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.68B | $602.8M | 50.0% | 28.3% | $235.0M | $91.9M |
| FY 2024 | $3.79B | $504.4M | 51.6% | 29.1% | $461.0M | $56.9M |
| FY 2023 | $3.96B | $400.1M | — | — | $377.0M | $41.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XRAY // BETA —
UFPT // BETA —